Provider Resources WA

03/30/22 Health Advisory: CDC endorses second booster dose of mRNA COVID-19 vaccine for certain groups

Syringe in vial

Requested actions Be aware, Centers for Disease Control and Prevention (CDC) and Western States Scientific Safety Review Workgroup endorsed Food and Drug Administration’s (FDA’s) emergency use authorization (EUA) of a second booster dose of Pfizer or Moderna COVID-19 vaccines for specific groups. The EUA allows: A second booster dose of Pfizer COVID-19 vaccine at least 03/30/22 Health Advisory: CDC endorses second booster dose of mRNA COVID-19 vaccine for certain groups

03/07/22 Health Advisory: Update on Johnson & Johnson vaccine ordering and guidance for healthcare settings

person wearing white coat and stethoscope writing on a clipboard

Requested actions Be aware, on March 4, Washington State Department of Health (DOH) discontinued ordering Johnson & Johnson COVID-19 vaccine because inventory is very low at Centers for Disease Control and Prevention (CDC) in Washington Immunization Information System (IIS). We encourage providers to post and look for available doses on IIS vaccine advertisement page. Email 03/07/22 Health Advisory: Update on Johnson & Johnson vaccine ordering and guidance for healthcare settings

02/25/22 Health Advisory: COVID-19 Updates for Providers

Four doctors talking as seen from above. Two with white coats and 2 in scrubs.

Requested actions Be aware, on Feb. 22, Centers for Disease Control and Prevention (CDC) revised its COVID-19 vaccine clinical considerations. An 8-week interval between first and second doses of mRNA COVID-19 vaccine (Moderna and Pfizer) may be optimal for males 12–39 years old to reduce risk of myocarditis and increase efficacy. CDC still recommends a 02/25/22 Health Advisory: COVID-19 Updates for Providers

02/14/22 Health Advisory: CDC Updated Covid-19 Vaccination Guidelines; FDA Postponed its pediatric Covid-19 Vaccination Review

person wearing white coat and stethoscope writing on a clipboard

COVID-19 Updates for Providers Requested actions Be aware, on February 11, the Centers for Disease Control and Prevention updated their guidance for COVID-19 vaccination to include: For people who are moderately or severely immunocompromised: People who have completed a primary series of an mRNA vaccine (Pfizer-BioNTech or Moderna) are recommended to receive an mRNA booster 02/14/22 Health Advisory: CDC Updated Covid-19 Vaccination Guidelines; FDA Postponed its pediatric Covid-19 Vaccination Review

02/01/22 Health Advisory: FDA Provides Full Approval For Spikevax

Female doctor with file in front of them with two other doctors at a microscope in the background.

COVID-19 Updates for Providers Requested actions Be aware, U.S. Food and Drug Administration (FDA) granted full authorization to Moderna COVID-19 vaccine for people 18 years or older. Evidence shows the vaccine is safe and effective and manufactured with high quality. The vaccine will now be called Spikevax but has the same formulation as emergency use 02/01/22 Health Advisory: FDA Provides Full Approval For Spikevax

01/06/22 Health Advisory: Booster Eligibility Expanded

Syringe in vial

COVID-19 Updates for Providers Requested actions Be aware, Centers for Disease Control and Prevention (CDC) endorsed Advisory Committee on Immunization Practices’ (ACIP’s) decision to strongly recommend a single Pfizer COVID-19 vaccine booster dose for people 12–17 years old at least 5 months after their primary series. This expands the age of booster access and strengthens 01/06/22 Health Advisory: Booster Eligibility Expanded

01/04/22 Health Advisory: CDC updated antiviral guidance

Exam room with vitals equipment on wall

COVID-19 Updates for Providers Requested actions Be aware, Centers for Disease Control and Prevention (CDC) updated its COVID-19 monoclonal antibody treatment recommendations. Sotrovimab monoclonal antibody formulation retains significant efficacy against Omicron, the dominant circulating variant. Other monoclonal antibody formulations under emergency use authorization (EUA)—bamlanivimab and etesevimab and casirivimab and imdevimab—lack clinical benefit against Omicron and 01/04/22 Health Advisory: CDC updated antiviral guidance